Advances in radiopharmaceuticals for cancer radiotheranostics: CCK2R targeting as a paradigm for translational innovation [0.03%]
癌症放射治疗药物的进展：CCK2R靶向作为转化创新的典范
Jing Li,Xuejun Wen,Rebeka Rita Reszegi et al.
Jing Li et al.
Radiopharmaceuticals are reshaping the landscape of cancer therapy, offering a unique theranostic advantage that is becoming increasingly central to precision medicine. By labeling the same molecular scaffold with different radionuclides, t...
Correction to "Improving antitumor immunity using antiangiogenic agents: Mechanistic insights, current progress, and clinical challenges" [0.03%]
“利用抗血管生成剂改善抗肿瘤免疫：机制见解、当前进展和临床挑战”的勘误子刊文章标题：利用抗血管生成剂改善抗肿瘤免疫：机制见解、现有成果及临床挑战
Published Erratum
Cancer communications (London, England). 2025 Sep 10. DOI:10.1002/cac2.70060 2025
Neoadjuvant chemoradiotherapy with capecitabine and irinotecan guided by UGT1A1 status in patients with locally advanced rectal cancer: 5-year update of the CinClare trial [0.03%]
基于UGT1A1基因状态引导的卡培他滨和伊立替康新辅助化放疗治疗局部晚期直肠癌：CinClare研究五年随访结果
Zhen Zhang,Xinchen Sun,Anwen Liu et al.
Zhen Zhang et al.
Background: The optimal regimen and chemotherapy intensity are still under investigation for neoadjuvant treatment of locally advanced rectal cancer (LARC). The CinClare trial has demonstrated improved pathologic complete...
Risk of colorectal cancer by family history of both colorectal carcinomas and colorectal polyps: a nationwide cohort study [0.03%]
基于结直肠癌和结直肠息肉的家族史划分结直肠癌风险：一项全国性队列研究
Yuqing Hu,Elham Kharazmi,Qunfeng Liang et al.
Yuqing Hu et al.
Background: The increased risk of colorectal cancer (CRC) associated with family history of both colorectal in situ or invasive carcinomas (Stage 0 to IV) and colorectal polyps is attributed solely to family history of CR...
Lactylation in cancer biology: Unlocking new avenues for research and therapy [0.03%]
癌症生物学中的乳酰化：探索新的研究和治疗途径
Xiaoyu Hou,Zhenya Hong,Huimin Zen et al.
Xiaoyu Hou et al.
Lactylation, a newly identified post-translational modification, plays a multifaceted role in cancer biology by integrating epigenetic and non-epigenetic mechanisms. This review summarizes the latest research progress on lactylation, includ...
Mengru Wang,Zhen Qin,Xiu-Wu Bian et al.
Mengru Wang et al.
Macrophages are prevalent in multiple tumors and exhibit diverse and potent functional activities. Therapeutic reprogramming of macrophage phenotypes represents a promising strategy for cancer immunotherapy. Engineering chimeric antigen rec...
Bingjun Ha,Xuetao Cao
Bingjun Ha
Coordinated gene expression within sustained STAT3-associated chromatin conformations contributes to hepatocellular carcinoma progression [0.03%]
持续的STAT3相关染色质构型内的协调基因表达有助于肝细胞癌的发展
Sunyoung Jang,Sumin Yoon,Hyeokjun Yang et al.
Sunyoung Jang et al.
Background: Phosphorylated signal transducer and activator of transcription 3 (p-STAT3) has emerged as a critical modulator of hepatocellular carcinoma (HCC) progression. However, its role in three-dimensional (3D) chroma...
m6A-modified EHD1 controls PD-L1 endosomal trafficking to modulate immune evasion and immunotherapy responses in lung adenocarcinoma [0.03%]
肺腺癌中EHD1控制PD-L1囊泡转运以调控免疫逃逸和免疫治疗应答的新机制
Fanglin Tian,Jian Huang,Weina Fan et al.
Fanglin Tian et al.
Background: Eps15 homology domain (EHD) proteins, including EHD1 to EHD4, play vital roles in tumor progression. In this study, we aimed to investigate which specific EHD proteins, if any, are implicated in tumor immune e...